Long-term follow-up of patients ≥60 yr old with acute myeloid leukaemia treated with intensive chemotherapy: A randomised trial of aclarubicin vs. daunorubicin in combination with cytosine arabinoside and thioguanine

European Journal of Haematology

Volumn 68, Issue 6, 2002, Pages 376-381

  Oberg G ^a   Killander, A ^a   Bjoreman M ^b   Gahrton, G ^c   Grimfors, G ^c   Gruber, A ^c   Hast, R ^c,d   Lerner, R ^c,e   Liliemark, J ^c   Mattson, S ^f   Paul, C ^c   Simonsson, B ^a   Stalfelt, A M ^b   Stenke, L ^c,d   Tidefelt, U ^c   Uden A M ^e   Bjorkholm M ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

Acute myeloid leukaemia; Chemotherapy; Elderly patients

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

ACLARUBICIN; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; SURVIVAL RATE; THIOGUANINE; TIME FACTORS;

EID: 18544369779     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.00423.x     Document Type: Article

References (15)

1. LÖWENBERG B, ZITTOUN R, KERKHOFS H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-1274.
2. STAIB P, LATHAN B, KNOPPEL-SCHWARK S, et al. Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients. Ann Oncol 1998;9:221-223.
3. REIFFERS J, RAYNAL F, BROUSTED A. Acute myeloblastic leukemia in elderly patients. Treatment and prognostic factors. Cancer 1980;45:2816-2820.
4. FOON KA, ZIGHELBOIM J, YALE C, GALE RP. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 1981;58:467-470.
5. YAMADA K, NAKAMURA T, TSURUO T, et al. A phase II study of aclacinomycin A in acute leukemia in adults. Cancer Treat Rev 1980;7:177-182.
6. BJÖRKHOLM M, KILLANDER A, for the Leukemia Group of Middle Sweden (LGMS). Daunorubicin versus aclarubicin in combination with cytarabine and thioguanine in elderly patients with acute non-lymphocytic leukemia: a preliminary report. Eur J Haematol Suppl 1987;47:49-54.
7. BENNET JM, CATOVSKY D, DANIEL M, et al. Proposals for the classification of the acute leukemias. Br J Haematol 1976;33:451-485.
8. ARMITAGE P, BERRY G. Statistical Methods in Medical Research. 3rd edn. London: Blackwell Scientific Publications, 1994.
9. DE NULLY BROWN P, HOFFMANN T, HANSEN OP, et al. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML. Leukemia 1997;11:37-41.
10. WAHLIN A, MARKEVÄRN B, GOLOVLEVA I, NILSSON M. Prognostic significance of risk group stratificaton in elderly patients with acute myeloid leukaemia. Br J Haematol 2001;115:25-33.
11. GOLDSTONE A, BURNETT A, WHEATLEY K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood 2001; 98:1302-1311.
12. TILLY H, CASTAIGNE S, BORDESSOULE D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;8:272-279.
13. KAHN SB, BEGG CB, MAZZA JJ, BENNETT JM, BONNER H, GLICK JH. Full dose versus attenuated dose daunorubicin, cytosin arabinoside, and 6-thioguanine in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol 1984;2:865-870.
14. HANSEN OP, PEDERSEN-BJERGAARD J, ELLEGAARD J, et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia 1991;5:510-516.
15. WAHLIN A, HÖRNSTEN P, JONSSON H. Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur J Haematol 1991; 46:240-247.